Conquer Cancer Logo

*LOI deadline extended to April 15, 2021* 

Gateway Discovery Grant to Address Cancer Disparities in Clinical Trials

The Gateway Discovery Grant to Address Cancer Disparities in Clinical Trials is designed to provide funding to catalyze innovative clinical research with a strong potential impact on mitigating cancer health disparities and improving equitable access to cancer clinical trials. The grant will provide up to $1.5 million in funding for the direct costs of the research over a three- to five-year project period. Clinical trials may be focused to study any cancer type. This grant encourages submissions implemented by a multi-institutional team to facilitate collaboration and increase patient recruitment.

Conquer Cancer is the scientific partner for the Gateway Discovery Grant Program and provides scientific expertise and peer review. Gateway for Cancer Research is the grantor and provider of funding for the research grant. The grant recipient must agree to the Terms and Conditions of Gateway.


The intent of this grant is to support proposals focused on reducing disparities in minority and health disparity populations and improving equitable access to care for all people facing cancer. 

Historically underserved populations include:

  • Blacks/African Americans
  • Hispanics/Latinx
  • American Indians/Alaska Natives
  • Asian Americans
  • Native Hawaiians and other Pacific Islanders
  • socioeconomically disadvantaged populations
  • underserved rural populations
  • sexual and gender minorities

Proposals should identify and address system-level barriers and factors contributing to disparities in clinical trials and the delivery of care for all people with cancer.


Applications may be submitted by entities that engage in cancer research including:

  • Higher Education Institutions
  • University Medical Centers
  • Nonprofits Other Than Institutions of Higher Education
  • Government Organizations (may include medical centers and hospitals that have access to resources and infrastructure to support a research project) 
  • Foreign Institutions are eligible to apply
  • Multi-institutional collaboration is encouraged for this grant. The person indicated as the Lead Principal Investigator (Lead PI) in the grant application is the one who is personally and actively responsible for the conduct and oversight of the research and who is considered eligible by the Sponsor Institution to apply as PI for a grant.

Principal Investigators (PIs)

  • Must have a doctoral degree (including MD, PhD, MD/PhD, DO, DC, ND, DDS, DVM, ScD, DNS, PharmD, or equivalent doctoral degree) in the biomedical sciences or in a field applicable to cancer disparities research.
  • Must be a full-time employee of the sponsoring institution.
  • Has individual experience serving as PI, Co-PI or collaborator on human research protocols.
  • Has demonstrated ability to carry out the responsibilities of PI, including administrative management of protocols.
  • Physicians must have a valid, active medical license in the country where the research will be conducted at the time of application and during the entire period of the grant.
  • Be able to commit sufficient time and effort to assure successful progress of the clinical trial.
  • Only one application per Lead PI will be accepted for the Gateway Discovery Grant to Address Cancer Disparities in Clinical Trials, although individuals may serve as a co-PI or contribute to more than one application.
  • Postdoctoral or clinical research fellows or the equivalent who are working under the auspices of a scientific mentor are not eligible to apply.
  • There are no citizenship or geographic requirements. However, by submitting an application, an applicant applying from an institution located in a country in which he/she is not a citizen or a permanent resident assures that the visa status will provide sufficient time to complete the project and grant term at the institution from which he/she applied.

Members of the Project Team

  • Gateway funded trials must involve patient advocates: Investigators are required to consult with patient representatives and advocates to gather their input into the trial design.
  • The Team should include at least one young investigator (e.g., clinical research fellow; junior faculty member) that should play a key role in the project.
  • Other collaborators.

Applicants who are uncertain about their eligibility are encouraged to contact before starting an application. 

Application Instructions

This application requires a Letter of Intent. The LOI and full application must be submitted in accordance with the requirements and instructions of the Gateway Discovery Grant to Address Cancer Disparities in Clinical Trials Program Guidelines and Application Instructions by the application deadline. All application materials must be in English and must be submitted through the Application Portal. Paper applications or applications sent by e-mail or fax will not be accepted. If you have questions, please email

Key Dates

  • Letter of Intent Due: April 15, 2021, 11:59 PM ET
  • Letter of Intent Notification: On a rolling basis until April 15, 2021, 11:59 PM ET
  • Full Application Due*: August 16, 2021, 11:59 PM ET
  • Anticipated Notification of Award: March 2022
  • Anticipated Grant Start Date: July 1, 2022

*Only applicants who have received approval for their LOI will be eligible to submit a full application. 


The Gateway Discovery Grant Program is supported by: